Statements of Operations-Additional Information (Tables)

12 Months Ended

Jun. 30, 2023

Statements of Operations-Additional Information

Schedule of revenues disaggregated by major product category and geographic region

Net Sales by Product Type

For the Year Ended June 30	2023		2022		2021
Animal Health
MFAs and other	$	387,349	$	361,538	$	330,017
Nutritional specialties		172,504		157,196		142,760
Vaccines		99,998		88,321		72,939
Total Animal Health	$	659,851	$	607,055	$	545,716
Mineral Nutrition		242,656		259,512		220,560
Performance Products		75,382		75,694		67,074
Total	$	977,889	$	942,261	$	833,350

Net Sales by Region

For the Year Ended June 30	2023		2022		2021
United States	$	578,773	$	561,803	$	494,889
Latin America and Canada		219,846		191,047		166,325
Europe, Middle East and Africa		117,815		122,480		114,131
Asia Pacific		61,455		66,931		58,005
Total	$	977,889	$	942,261	$	833,350

Schedule of interest expense, net

For the Year Ended June 30	2023		2022		2021
Interest expense, net
2021 Term A loan	$	6,243	$	8,962	$	7,951
Revolving credit facility		10,905		2,956		3,649
2023 Incremental Term Loan		154		—		—
2022 Term loan		589		—		—
Amortization of debt issuance costs		727		590		833
Refinancing expense		—		—		1,020
Other		58		183		265
Interest expense		18,676		12,691		13,718
Interest income		(3,355)		(816)		(838)
	$	15,321	$	11,875	$	12,880

Schedule of depreciation and amortization

For the Year Ended June 30	2023		2022		2021
Depreciation and amortization
Depreciation of property, plant and equipment	$	24,316	$	23,781	$	23,165
Amortization of intangible assets		9,696		8,924		8,715
Amortization of other assets		—		—		5
	$	34,012	$	32,705	$	31,885

Schedule of amortization of intangible assets

For the Year Ending June 30
2024	$	9,375
2025		7,769
2026		6,805
2027		6,556
2028		6,531
Thereafter		17,951
Total	$	54,987

Schedule of research and development expense

For the Year Ended June 30	2023		2022		2021
Research and development expense	$	24,395	$	20,832	$	17,759